Sinntaxis was founded 2017 by scientists at Lund University and LU Holding AB. The company is managed by a team with vast experience in neuroscience/stroke research and pharmaceutical drug development and business development. Sinntaxis has an established discovery platform for preclinical studies of stroke recovery, and has filed IP on the use of negative allosteric modulators of the metabotropic glutamate receptor 5 for the treatment of stroke recovery. Sinntaxis has established a global network of Key Opinion Leaders ranging from experimental research to clinical trial in stroke recovery.